Location History:
- Mikunihonmachi, Yodogawa-ku, Osaka, JP (1991)
- Yodogawa-ku, Osaka-shi, Osaka JP (1995)
- Fukuoka, JP (1991 - 2016)
Company Filing History:
1 out of 1,384 
1 out of 25 
1 out of 1 
Years Active: 1991-2016
Title: Michihiro Fujiwara: Innovator in Therapeutic Agents for Dementia
Introduction
Michihiro Fujiwara is a notable inventor based in Fukuoka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in developing therapeutic agents for dementia. With a total of nine patents to his name, Fujiwara's work focuses on innovative solutions for treating ischemic disorders.
Latest Patents
One of Fujiwara's latest patents is a therapeutic agent for dementia. This invention comprises a pharmaceutically active substance derived from an inhibitor of ischemic disorders. The aim is to provide a drug that is effective in treating and preventing diseases where ischemia or inflammatory substances associated with ischemia contribute to the onset or worsening of conditions. The active ingredients include farnesol, farnesol derivatives, tocopherol derivatives, tocotrienol derivatives, and their pharmacologically acceptable salts and solvates. This inhibitor can exert therapeutic and preventive effects on diseases such as brain infarction and cardiac infarction, not only during the acute ischemic stage but also in subacute and chronic stages after ischemia-reperfusion. Additionally, Fujiwara's patent includes a farnesol carboxylic acid ester derivative and a method for producing it.
Career Highlights
Throughout his career, Michihiro Fujiwara has worked with various companies, including Schering Aktiengesellschaft. His expertise in pharmaceutical innovation has led to advancements in treatments for serious health conditions.
Collaborations
Fujiwara has collaborated with notable individuals in his field, including Kenichi Mishima and Jiro Takata. These partnerships have contributed to the development of his innovative therapeutic agents.
Conclusion
Michihiro Fujiwara's work in developing therapeutic agents for dementia showcases his commitment to addressing critical health issues through innovation. His contributions to the field are significant and continue to impact the pharmaceutical industry positively.